
302: Why Rushing Cell Line Development Costs You Months Later: The Analytics-First CMC Strategy with Lars Stöckl and Lena Tholen - Part 2
Notas do episódio
Biologics development is full of hidden pitfalls, from selecting the right cell line to navigating analytical assessments that can make or break a therapy's success.
Today, we feature Lars Stöckl and Lena Tholen, industry experts from FyoniBio GmbH, who have deep experience guiding biotech teams through the maze of CMC development, troubleshooting both common and unusual product quality challenges.
Topics discussed:
- Key factors in selecting host cell lines and the importance of matching the platform to molecule complexity (02:34)
- The role of broad analytical assays early in cell line and pool development for better decision-making (03:34)
- Glycosylation, post-translational modifications, and analytical strategies for both standard antibodies and more complex biotherapeutics (05:10)
- When and how to conduct developability and manufacturability assessments, especially for novel or specialized molecules (06:55)
- Troubleshooting glycosylation and aggregation problems—when to tweak the process and when to reconsider the molecule (08:05)
- Importance of clear, direct communication with clients regarding manufacturability and process viability (09:32)
- Example of how different CHO cell lines can dramatically impact molecule outcome and company trajectory (12:08)
- Keeping pace with technological advances through collaboration, conferences, and feasibility studies with startups (13:55)
- The move toward customization over standardization in cell line and process development (18:07)
Smart insight: The future of bioprocess development lies in a customized, molecule-centric approach. Rather than relying on generic, pre-set development platforms, success comes from carefully matching cell lines, processes, and analytical methods to the unique requirements of each molecule. True innovation and commercial success arise from adapting everything—cell line, process, analytics—to the molecule at hand.
Lars and Lena’s main point is that early choices about the host cell line, the analytics and the partner decide what’s possible later on. The episodes below take that idea further. One looks at the mechanics of cell line development, one at why promising molecules fail to manufacture, and two at outsourcing CMC work from the sponsor’s side.
- Episodes 117 - 118: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough
- Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
- Episodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist’s Guide to CDMO Selection with Sigma Mostafa
- Episodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark Melville
Connect with Lars Stöckl and Lena Tholen:
Website: www.fyonibio.com
LinkedIn:www.linkedin.com/in/dr-lars-stoeckl
LinkedIn: www.linkedin.com/in/lena-tholen-80642a11a